GRIHealthcare · BiotechnologyGRI Stock Forecast: GRI Bio, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering GRI Bio, Inc. hold a median 12-month price target of $21 — +1358.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
GRI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores GRI Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own GRI Bio, Inc. — and when they’d sell — is the membership.
GRI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1358.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | $40 → $32 |
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 11 Mar 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 14 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Dec 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 8 Oct 2024 | Ascendiant Capital | Initiates | Buy | $12 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GRI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
GRI Bio, Inc. (GRI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- 0.8×
Cheaper than 73% of US stocks
Cheaper than 88% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −185.7%
- Return on assets
- −88.8%
- Dividend yield
- 148.1%
Higher than 7% of US stocks
Higher than 3% of US stocks
Higher than 98% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GRI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRI appears on the weeks it earns a place.
Frequently asked questions about GRI stock
What is the GRI stock price forecast for 2026-2027?
The 2 Wall Street analysts covering GRI Bio, Inc. have a median 12-month price target of $21, with estimates ranging from $10 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GRI stock a buy right now?
Of the 2 analysts covering GRI Bio, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRI Bio, Inc. 21 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GRI?
As at 1 Aug 2026, GRI Bio, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
Will GRI stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1358.3% from the last close, and Ticker Nerd's factor model ranks GRI Bio, Inc. 21 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GRI stock forecast for 2030?
No analyst covering GRI Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $32 over the next 12 months.
How has GRI stock performed over the past year?
GRI Bio, Inc. returned -96.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does GRI Bio, Inc. do?
Gri Bio Inc. is a biotechnology company dedicated to the development of innovative therapies, particularly focusing on immunology and inflammatory diseases.
About GRI Bio, Inc.
Gri Bio Inc. is a biotechnology company dedicated to the development of innovative therapies, particularly focusing on immunology and inflammatory diseases. The primary function of the company is to research and create novel treatments that address unmet medical needs, leveraging cutting-edge scientific discoveries to advance human health. Their work predominantly impacts the healthcare and pharmaceutical sectors, with a significant emphasis on improving patient outcomes in challenging disease areas. Gri Bio Inc. plays a crucial role in the biotechnology market, contributing to the expansive growth and diversification of therapeutic options available to clinicians. By prioritizing transparency, collaboration, and rigorous scientific evaluation, the company aims to foster substantial progress within the biotech field, offering valuable advancements in medicine to stakeholders, including patients, healthcare providers, and the broader scientific community. Gri Bio Inc.'s commitment to excellence and pioneering research propels its significance and potential influence in the financial markets by addressing critical health challenges through breakthrough therapies.
CEO Dr. W. Marc Hertz Ph.D. · 3 employees · United States · https://www.gribio.com